Researchers test effects of full doses of anticoagulants in COVID-19 patients
Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients.
Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, full-dose anticoagulation drugs did not improve outcomes. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.
As is normal for clinical trials, these trials are overseen by independent boards that routinely review the data and are composed of experts in ethics, biostatistics, clinical trials, and blood clotting disorders. Informed by the deliberations of these oversight boards, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19.
WINNIPEG The University of Manitoba is pausing a clinical trial examining the use of blood thinners to help treat certain patients with COVID-19 The announcement was made in a news release on Tuesday, and affects critically ill patients who were in the ICU. The trial is part of three clinical trial platforms testing the effects of full doses of blood thinners in COVID-19 patients. The trials were launched as clinicians noticed that many COVID-19 patients, including those who died from the disease, formed blood clots throughout their bodies. However, the trials found blood thinners did not improve outcomes for critically ill patients who required ICU support.
Credit: n/a
December 22 - Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, full dose anticoagulation drugs did not improve outcomes. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.
As is normal for clinical trials, these trials are overseen by independent boards that routinely review the data and are composed of experts in ethics, biostatistics, clinical trials, and blood clotting disorders. Informed by the deliberations of these oversight boards, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19. A potential for harm in this sub-group could not be excluded. Increased bleeding is a known complication of full-dose anticoagulation. The trials are working urgently to u
Manitoba team embeds research in COVID-19 care
Last Modified: 8:38 AM CST Monday, Dec. 14, 2020 | Updates
photos by MIKE DEAL / WINNIPEG FREE PRESS
Research co-ordinators Nora Choi, outside Grace Hospital, and Quinn Tays, outside St. Boniface General Hospital (below), are working with a team of researchers from other Winnipeg hospitals co-ordinating clinical trials with COVID-19 patients.
As COVID-19 hospitalization rates in the province continue to push intensive care units beyond their limits, a small team of local researchers is chasing the virus most of the world has been told to avoid at any cost.
As COVID-19 hospitalization rates in the province continue to push intensive care units beyond their limits, a small team of local researchers is chasing the virus most of the world has been told to avoid at any cost.